KDR and neoplasm: Additionally, apatinib is a potent vascular endothelial growth factor receptor 2 (VEGFR-2) inhibitor, which can inhibit tumor neovascularization after TACE and play an anticancer role by effectively binding and inhibiting VEGFR-2 [10, 11].